Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
about
Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes.Contributions of human enzymes in carcinogen metabolismInvestigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models.PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.Oxazaphosphorines: new therapeutic strategies for an old class of drugs.Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4.Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivoHydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.Clinical implications of CYP3A polymorphisms.Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" ProblemPharmGKB summary: very important pharmacogene information for CYP3A5.Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co-culture biochip.Comparison of the novel HK-2 human renal proximal tubular cell line with the standard LLC-PK1 cell line in studying drug-induced nephrotoxicity.Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6.Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.
P2860
Q30357429-2B276DBA-F6AC-461F-A3CD-F59922A0AAA8Q30520640-7748D93E-1E0B-44D9-8A16-662557FE4A3EQ30979147-21DB6B80-562F-45DE-94D2-656CB02CFD59Q33855506-8FC43259-9FCD-4E49-99EA-BBBBA06CA6C4Q34113899-4A917EF9-C979-493A-A01E-61B8EB3A8A68Q34146529-944A1D42-251A-4750-A490-977148675716Q34325249-F240EEC4-BF06-455C-940C-61FA1EF79AF2Q35647150-0C4B0EA0-A698-450E-B7E2-3C569AB6E46BQ35745249-B4C7FFFE-9CA9-4141-BE10-68B5CBA96126Q36546247-27007760-E6A8-4F52-851F-7A902BFD0E4CQ36634077-CFBE7C63-A261-4F64-8F00-1618FC1A01A5Q37081741-0B05D6AC-3C63-4E71-8476-F2351ACF816AQ37386327-1B9EA5CE-2369-44E0-B9A1-09976042275AQ39570346-5227F8EA-BCC7-4D70-B8C8-88BB516D4189Q39691802-BE4009B8-865E-44BD-B83C-700F3A6CF1CBQ40253486-CC20C4FD-A1D7-45C6-B679-9E79F146108AQ41677104-EBD5AAF7-BA3E-483B-8978-753B4D1D48D7Q53233045-ADB5A07C-713C-4B84-A37E-DA41793F6E8B
P2860
Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
@en
Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
@nl
type
label
Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
@en
Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
@nl
prefLabel
Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
@en
Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
@nl
P2093
P356
P1476
Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
@en
P2093
Brian R Phillips
Danny D Shen
David Blough
Kenneth E Thummel
Linda J Risler
P304
P356
10.1124/DMD.104.002279
P577
2005-04-08T00:00:00Z